Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, UK.
Am Heart J. 2011 Mar;161(3):431-8. doi: 10.1016/j.ahj.2010.10.042.
With cardiovascular disease (CVD) emerging as a major cause of mortality in India, clinical research in CVD is becoming increasingly important. There are several favorable factors that offer robust growth of clinical research infrastructure in India: well-established system of governance, a large investment in medical education infrastructure, growing interest in building capacity in clinical research, the presence of regulatory mechanisms governing clinical research, a large pharmaceutical industry, and a highly developed information technology and data processing infrastructure. However, the lack of trained research manpower, inadequate public spending on health, uneven distribution of health infrastructure, and the large prevalence of pretransitional diseases are major weakness in undertaking high-quality clinical research in CVD. Analysis of the contemporary scenario reveals that there are 3 important opportunities for clinical research in India: the need to identify low cost but cutting edge and context-specific interventions to address the health needs of India's large population, the potential for high-quality research, and the high degree of interest (domestically and internationally) in investing in clinical research education and infrastructure.
随着心血管疾病 (CVD) 在印度成为主要死亡原因，CVD 的临床研究变得日益重要。印度临床研究基础设施稳健增长有几个有利因素：完善的治理体系、对医疗教育基础设施的大量投资、对临床研究能力建设的兴趣日益浓厚、监管临床研究的机制、庞大的制药业，以及高度发达的信息技术和数据处理基础设施。然而，缺乏训练有素的研究人力、公共卫生支出不足、卫生基础设施分布不均，以及前过渡性疾病的高流行率，这些都是在 CVD 中开展高质量临床研究的主要弱点。对当代情况的分析表明，印度的临床研究有 3 个重要机遇：需要确定低成本但前沿和特定于背景的干预措施，以满足印度庞大人口的健康需求；高质量研究的潜力；以及国内外对临床研究教育和基础设施投资的高度兴趣。
